From the Chief Medical Officer Professor Sir Michael McBride



HSS(MD) 18/2024

FOR ACTION

Chief Executives, Public Health Agency/HSC Trusts/NIAS
Deputy Secretary SPPG
GP Medical Advisers, SPPG
All General Practitioners and GP Locums (for onward
distribution to practice staff)
OOHs Medical Managers (for onward distribution to staff)

BELFAST BT4 3SQ

Castle Buildings Stormont Estate

Tel: 028 9052 0563

Email: <u>Michael.McBride@health-ni.gov.uk</u>

Our Ref: HSS(MD) 18/2024

Date: 29 May 2024

PLEASE SEE ATTACHED FULL CIRCULATION LIST

Dear Colleague

NATIONAL PATIENT SAFETY ALERT – SHORTAGE OF PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)

Actions for clinicians, prescribers and dispensers of PERT, to remain in place <u>only</u> <u>until the supply issues have resolved</u> (see SPS Medicine Supply Tool):

- 1. Clinicians should:
 - a. Prescribe a maximum of one month's supply of PERT for all patients at a time.
 - b. Prioritise available Creon® 10,000 capsules for patients unable to take Creon® 25,000 capsules only.
 - c. Prioritise remaining stock of Nutrizym® 22 capsules for patients unable to tolerate Creon® capsules.
 - d. Where PERT is prescribed for indications other than cystic fibrosis, clinicians and prescribers should consider:
 - prescribing a proton pump inhibitor or H2 receptor antagonist to optimise efficacy
 - if a dose reduction may be suitable for patients based on severity of symptoms
 - where symptoms remain despite a dose of ≥10,000 units lipase/kg/day or 100,000 units lipase with a meal, whether other causes of the symptoms should be investigated
 - prescribing medication to manage symptom control

- e. prescribe unlicensed imports of PERT only where licensed alternatives are unavailable, working with local pharmacy teams to ensure orders are placed within appropriate time frames.
- f. immediately refer patients to a specialist for advice on alternative treatments if above options are not suitable.
- 2. Pharmacists presented with repeat prescription for PERT should only supply the equivalent to one month's supply in accordance with <u>SSP060</u> and <u>SSP061</u>.

Summary of identified safety issue

This alert supersedes the Medicine Supply Notification (MPS 3202) issued on the 9 May 2024.

There are limited supplies of pancreatic enzyme replacement therapies (PERT).

- Creon® 10,000 and 25,000 capsules are in limited supply until 2026.
- Nutrizym® 22 capsules are out of stock until mid-August 2024.
- Pancrex V® capsules and powder remain available but are unable to support an increase in demand.

The supply disruption of Creon® capsules is due to limited availability of active pharmaceutical ingredients and manufacturing constraints to produce the volumes required to meet demand.

The supply disruption for Nutrizym® 22 capsules has been caused by a manufacturing issue and increased demand because of the Creon® supply issue.

PERT is indicated for the treatment of pancreatic exocrine insufficiency such as in cystic fibrosis, pancreatic cancer, and pancreatitis. There is no clinical alternative to PERT.

Unlicensed imports of Creon® capsules and alternative brands of PERT may be sourced, lead times vary.

Information relating to imports is available below and on the SPS Medicines Supply Tool which also details any changes to resupply dates, updates to this communication and an up-to-date supply overview.

Additional information

Clinical Information

Creon® gastro-resistant capsules and Nutrizym® 22 capsules are licensed for the treatment of pancreatic exocrine insufficiency. Each preparation contains different amounts of pancreatic enzymes. Many patients adjust their dose according to symptom management, but all patients should be counselled to re-titrate the dose if problems with digestion or weight loss occur.

Supply of Creon® 10,000 capsules should be reserved for patients unable to take Creon® 25,000 capsules only. Where patients are prescribed Creon® 10,000 due to swallowing difficulties, consider the suitability of prescribing Creon® 25,000 capsules which may be opened and mixed (without crushing) with soft acidic food (e.g., apple sauce or yoghurt). It is very important granules are not chewed or mixed with hot food. Patients should be counselled on oral care, including rinsing the mouth after eating, and ensuring dentures are cleaned regularly as granules can get stuck in the gums and under dentures and cause ulceration.

For advice on the use of reduced doses, optimisation of doses, and symptom control, please refer to the clinical advice in this <u>position statement</u>, endorsed by a number of professional bodies. Please note that medication prescribed for symptom control will not treat malabsorption and should not be considered as alternative to PERT.

The following specialist importers have confirmed they can source unlicensed PERT preparations (please note there may be other companies that can also source supplies):

The enzyme composition of unlicensed imports may differ from UK licensed products; please refer to corresponding Summary of Product Characteristics for specific product information.

- Alium (PANCREAZE® Delayed-Release Capsules)
- Durbin (Zenpep® Delayed-Release Capsules)
- Mawdsleys (Creon®)
- Smartway (Creon®)
- Target (Creon®, PANCREAZE® Delayed-Release Capsules, Zenpep® Delayed-Release Capsules)

References

- SPC Creon gastro-resistant capsules
- SPC Nutrizym gastro-resistant capsules
- SPC Pancrex V
- BNF: Pancreatin

Mudrail My Great

- UK Guidelines on the management of pancreatic exocrine insufficiency
- Position Statement: PERT Shortage
- SPS Medicine Supply Tool
- Serious Shortage Protocols

Yours sincerely

PROFESSOR SIR MICHAEL McBRIDE

Chief Medical Officer

PROFESSOR CATHY HARRISON Chief Pharmaceutical Officer

Circulation List

Director of Public Health/Medical Director, Public Health Agency (for onward distribution to all relevant health protection staff)

Assistant Director Public Health (Health Protection), Public Health Agency

Director of Nursing, Public Health Agency

Assistant Director of Pharmacy and Medicines Management, SPPG (for onward distribution to Community Pharmacies)

Directors of Pharmacy HSC Trusts

Director of Social Care and Children, SPPG

Family Practitioner Service Leads, SPPG (for cascade to GP Out of Hours services)

Medical Directors, HSC Trusts (for onward distribution to all Consultants,

Occupational Health Physicians and School Medical Leads)

Nursing Directors, HSC Trusts (for onward distribution to all Community Nurses, and Midwives)

Directors of Children's Services, HSC Trusts

RQIA (for onward transmission to all independent providers including independent hospitals)

Joe Brogan, Assistant Director, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group (SPPG) (for onward distribution to SPPG Pharmacy and Medicines Management Team and community pharmacists)

Regional Medicines Information Service, Belfast HSC Trust

Regional Pharmaceutical Procurement Service, Northern HSC Trust

Professor Donna Fitzsimons, Head of School of Nursing and Midwifery QUB

Professor Neal Cook, Head of School of Nursing, University of Ulster

Heather Finlay, CEC

Donna Gallagher, Open University

Professor Paul McCarron, Head of School of Pharmacy and Pharmaceutical Sciences, UU

Professor Colin McCoy, Head of School, School of Pharmacy, QUB

Postgraduate Pharmacy Dean, NI Centre for Pharmacy

Learning and Development, QUB

Michael Donaldson, Head of Dental Services, SPPG (for distribution to all General Dental Practitioners)

Raymond Curran, Head of Ophthalmic Services, SPPG (for distribution to Community Optometrists)

Trade Union Side

Clinical Advisory Team

Louise McMahon, Director of Integrated Care, SPPG

This letter is available on the Department of Health website at

 $\frac{https://www.health-ni.gov.uk/topics/professional-medical-and-environmental-health-advice/hssmd-letters-and-urgent-communications}{}$